Senti Biosciences (SNTI) has received a new Buy rating, initiated by Leerink Partners analyst, Jeffrey La Rosa.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jeffrey La Rosa has given his Buy rating due to a combination of factors that highlight the potential of Senti Biosciences’ innovative approach in treating acute myeloid leukemia (AML). The company’s Logic-Gated gene circuit platform is designed to address the challenges associated with cell therapies targeting cancers with complex antigen profiles. Their lead candidate, SENTI-202, is a CAR-NK cell therapy that is currently in Phase 1 trials for relapsed or refractory AML, a condition known for its treatment resistance and patient frailty.
La Rosa emphasizes the unique design of SENTI-202, which includes an “OR-gate” to tackle tumor heterogeneity, a “NOT-gate” to minimize off-target effects, and a slow-release IL-15 transgene to boost potency. This design aims to overcome the limitations of existing therapies and improve patient outcomes. Furthermore, the preliminary data from the Phase 1 trials support the potential of SENTI-202 to offer a differentiated clinical profile. Despite the early stage of clinical signals, the projected peak sales and the strategic presentation at the American Society of Hematology indicate positive momentum for Senti Biosciences.
In another report released on November 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.